Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14910269 | 1.00 | SYK (0.43) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL8230634 | 1.00 | SYK (0.43) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL2013068 | 0.92 | CA1 (0.44) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL9971702 | 0.87 | CA1 (0.39) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL14842453 | 0.87 | CA1 (0.38) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL16808055 | 0.86 | CA1 (0.40) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL8076295 | 0.85 | CTSK (0.48) | CTSKCTSSCA1CA7CA12 | |
| SCHEMBL8076292 | 0.85 | CTSK (0.48) | CTSKCTSSCA1CA7CA12 | |
| SCHEMBL4945179 | 0.85 | CA1 (0.39) | SYKCTSKCTSSCA1CA7 | |
| SCHEMBL6333451 | 0.85 | CA1 (0.39) | SYKCTSKCTSSCA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| US-20160016962-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970304-A1 | P2X7 MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290190-A1 | [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-15 | — | — | US | disclosed |
| US-9040534-B2 | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-6706881-B2 | 4-(METHOXYCARBONYL-AMINO)-2-ETHYL-6-TRIFLUOROMETHYL-3,4-DIHYDRO -2H-QUINOLINE-1-CARBOXYLIC ACID ETHYL ESTER IS REACTED WITH 3,5-BIS(TRIFLUOROMETHYL)BENZYL HALIDE IN BASE; ALKYLATION | PFIZER, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6689897-B2 | CHOLESTERYL ESTER TRANSFER PROTEIN | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| EP-1383734-A2 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002088069-A9 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PROD INC (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030216576-A1 | Methods for preparing CETP inhibitors | PFIZER INC. | 2003-11-20 | — | — | US | disclosed |
| US-6600045-B2 | This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors and intermediates useful in the preparation of said CETP inhibitors. | PFIZER INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030073843-A1 | Methods for preparing CETP inhibitors | DAMON DAVID B (US) | 2003-04-17 | — | — | US | disclosed |
| US-20020177716-A1 | Intermediates of CETP inhibitors | DAMON DAVID B (US) | 2002-11-28 | — | — | US | disclosed |
| WO-2002088069-A2 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088085-A2 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216576-A1 | Methods for preparing CETP inhibitors | CETP, LCAT, MTTP | SYK 4353/4885CTSK 570/4885CTSS 400/4885 |
| US-20160016962-A1 | P2X7 MODULATORS | P2RX5, P2RX1, P2RX7 | SYK 742/4885CTSK 346/4885CTSS 147/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | SYK 201/4885CTSK 1998/4885CTSS 1752/4885 |
| US-20150290190-A1 | [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS | P2RX7, P2RX5, P2RX2 | SYK 1905/4885CTSK 1854/4885CTSS 3201/4885 |
| US-10053463-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | HTR5A, P2RX5, P2RX3 | SYK 732/4885CTSK 284/4885CTSS 176/4885 |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | RNMT, RNGTT, CAPG | SYK 4313/4885CTSK 2249/4885CTSS 3005/4885 |
| US-20030073843-A1 | Methods for preparing CETP inhibitors | CETP, LCAT, MTTP | SYK 4353/4885CTSK 570/4885CTSS 400/4885 |
| US-20020177716-A1 | Intermediates of CETP inhibitors | CETP, LCAT, MTTP | SYK 4471/4885CTSK 362/4885CTSS 379/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | SYK 1777/4885CTSK 1276/4885CTSS 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.